Summary
This 8-K filing from E. I. du Pont de Nemours and Company (DuPont) reports a mutual agreement with The Dow Chemical Company (Dow) to grant the European Commission a 10-working day extension for its Phase II review of their proposed merger of equals. This extension is a routine procedural step under the EU Merger Regulation and indicates ongoing constructive engagement with the Commission to address concerns and secure approval. While the companies remain confident in obtaining clearance and are focused on closing the transaction by year-end 2016, the extension, if fully utilized, would push the expected closing into early 2017, subject to customary closing conditions. Investors should note that this development, while not unexpected, highlights the ongoing regulatory scrutiny. The company emphasizes its commitment to working through the process and reiterates its forward-looking statements regarding the merger's completion and anticipated benefits. However, the filing also includes a comprehensive cautionary note detailing numerous risks and uncertainties that could impact the transaction's timing, terms, integration, and the combined company's future performance, including potential litigation, business disruptions, and challenges in achieving anticipated synergies.
Key Highlights
- 1DuPont and Dow have agreed to a 10-working day extension for the European Commission's Phase II review of their proposed merger.
- 2The extension is described as a routine occurrence under the EU Merger Regulation.
- 3The companies are actively working with the European Commission to address concerns and obtain regulatory approval.
- 4DuPont and Dow remain confident in their ability to achieve merger clearance.
- 5The target closing date remains the end of 2016, but a full extension could push closing to early 2017.
- 6The filing reiterates comprehensive cautionary statements about risks and uncertainties associated with the merger and its potential impact.